T-DM1 protects against invasive disease
T-DM1 protects against invasive disease
复制标题
DOI：
10.1038/s41571-018-0164-2
复制
发表时间：
2019-01
影响因子：
78.8
通讯作者：
P. Sidaway
中科院分区：
文献类型：
--
作者：
P. Sidaway
HER 2阳性乳腺癌新辅助治疗后残留病灶的女性患者的长期预后较差。现在，来自凯瑟琳试验的数据，一项III期开放标签研究，揭示了抗体-药物偶联物曲妥珠单抗-美坦新偶联物的优越性（由与细胞毒性微管抑制剂emtansine缀合的曲妥珠单抗组成; T-DM 1）在改善这种情况下的结果。共有1,486名非转移性，在以紫杉烷为基础的新辅助化疗加曲妥珠单抗随后手术后有残留病变的浸润性原发性乳腺癌患者被随机分配（1：1）接受14个周期，包括3周静脉内剂量的辅助T-DM 1或曲妥珠单抗。主要终点为无侵袭性疾病生存期（DFS）。
Women with residual disease following neoadjuvant therapy for HER2-positive breast cancer have inferior long-term outcomes. Now, data from the KATHERINE trial, a phase III open-label study, reveal the superiority of the antibody–drug conjugate trastuzumab emtansine (consisting of trastuzumab conjugated to the cytotoxic microtubule inhibitor emtansine; T-DM1) in improving outcomes in this setting.A total of 1,486 women with nonmetastatic, invasive primary breast cancer with residual disease after neoadjuvant taxane-based chemotherapy plus trastuzumab followed by surgery were randomly assigned (1: 1) to receive 14 cycles, consisting of 3-weekly intravenous doses of adjuvant T-DM1 or trastuzumab. The primary end point was invasive disease-free survival (DFS).